title: Heparin therapy for ulcerative colitis? Effects and mechanisms.
abstract: Despite intensive medical treatment with steroids and immunosuppressants, acute colitis is still associated with a colectomy rate of up to 15%. Following the observation that a patient with severe steroid-resistant colitis went into remission when treated with heparin for a deep vein thrombosis, there have been a number of reports on the use of heparin in acute ulcerative colitis. Although small and uncontrolled, these studies consistently demonstrate the beneficial effects of heparin, with surprisingly few side-effects in a disease characterized by mucosal haemorrhage. The mechanisms by which heparin may ameliorate ulcerative colitis remain unclear. A simple anticoagulant effect may be responsible, but similar effects are not seen with warfarin. As a result of their intense negative charge, the glycosaminoglycans that constitute heparin have diverse biological effects. These include potent anti-inflammatory actions, in vitro and in vivo, and the potentiation of the activity of the peptide growth factors necessary for mucosal regeneration and repair. This review summarizes the clinical reports on heparin treatment for ulcerative colitis and explores the mechanisms by which this novel form of treatment may exert its effects.
authors.affiliation: Department of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
authors.forename: N P
authors.initials: NP
authors.lastname: Michell
authors.forename: P
authors.initials: P
authors.lastname: Lalor
authors.forename: M J
authors.initials: MJ
authors.lastname: Langman
mesh_terms: D000276:Adjuvants, Immunologic; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000503:physiopathology; D003106:Colon / Q000187:drug effects; D016222:Fibroblast Growth Factor 2 / Q000502:physiology; D006025:Glycosaminoglycans / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009504:Neutrophils / Q000502:physiology; D013002:Somatomedins / Q000627:therapeutic use; D014945:Wound Healing
chemical_list: D000276:Adjuvants, Immunologic; D000925:Anticoagulants; D006025:Glycosaminoglycans; D013002:Somatomedins; D016222:Fibroblast Growth Factor 2; D006493:Heparin